Small Molecules

06 Mar 2007 Neoprobe Announces Interim Phase 2 Lymphoseek Results
06 Mar 2007 Myriad Presents Additional Flurizan(TM) Phase 2 Study Data Demonstrating Benefit in Alzheimer's Patients
06 Mar 2007 Arena Pharmaceuticals Initiates Phase 2 Clinical Trial of APD125 for the Treatment of Insomnia
06 Mar 2007 LAB International Announces Positive Results From The Open-Label Phase IIB Fentanyl Taifun(R) Trial
06 Mar 2007 AD 923 Commences Phase 1 Clinical Development in the USA
06 Mar 2007 AlphaRx Announces Completion of Phase II Clinical Trial for Indaflex
06 Mar 2007 Actelion: Positive Study With Bosentan (Tracleer) in CTEPH
06 Mar 2007 Biocryst And Shionogi Establish Collaboration In Japan
06 Mar 2007 YM BioSciences completes enrolment of AeroLEF(TM) Phase IIB pain trial
03 Mar 2007 Sebivo(R) approved in China for treatment of chronic hepatitis B, the nation's second leading cause of death
03 Mar 2007 FDA Approves Astellas' Vaprisol for the Treatment of Hypervolemic Hyponatremia
03 Mar 2007 Lipitor Significantly Reduced the Risk of Serious Cardiovascular Events Compared With Simvastatin in an 80,000-Patient Analysis of a Real-World Managed Care Database
02 Mar 2007 Pfizer's Maraviroc, Novel Medicine For HIV, Significantly Reduces Viral Load, in Combination Therapy Across Range of Treatment-Experienced Patients
02 Mar 2007 Sunesis Pharmaceuticals Files Investigational New Drug Application for Novel Aurora Kinase Inhibitor, SNS-314
02 Mar 2007 EMEA Accepts for Review Thalidomide Pharmion(R) Marketing Authorization Application for Untreated Multiple Myeloma
02 Mar 2007 Insert Therapeutics Signs New Partnership With R&D Biopharmaceuticals
02 Mar 2007 KeyNeurotek AG and Grünenthal GmbH sign exclusive licensing agreement for drug development and marketing
02 Mar 2007 Point Therapeutics Provides Clinical Update
02 Mar 2007 CollaGenex Pharmaceuticals Announces Positive Results of Phase 2 Dose-Finding Study of Incyclinide for the Treatment of Acne
02 Mar 2007 New Data on Investigational Agent TMC278 in Anitretroviral-Naive HIV Patients
02 Mar 2007 Results from Two Phase III Studies on ISENTRESS(TM) (raltegravir, MK-0518), Merck's Oral Investigational Integrase Inhibitor Presented at the Annual Conference on Retroviruses and Opportunistic Infections (CROI)
02 Mar 2007 Preclinical Data From Two Novel Idenix Compounds for the Treatment of HIV Presented at Conference on Retroviruses and Opportunistic Infections (CROI)
02 Mar 2007 Gilead Announces 24-Week Results from Phase II Study of Investigational HIV Integrase Inhibitor GS 9137
01 Mar 2007 Evotec and Interprotein Sign Collaboration Agreement to Develop Interleukin 6 Inhibitors to Treat Inflammatory Diseases
01 Mar 2007 Pharmasset Initiates Multiple Ascending Dose Study of R7128 in Patients Chronically Infected with HCV Genotype 1

La Merie Biologics

FREE Weekly News Bulletin

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top